“Globalization is (Almost) Dead” – New Book by FT Columnist Rana Foroohar Explains Why
Financial Times columnist Rana Foroohar writes about the end times for globalization as we know. What comes next in the post-global world?
JP Morgan CEO Jamie Dimon, Others, Tell Congress They’ll Leave China If Told
Washington proves to be more hawkish on China than Wall Street. Especially in the House of Representatives. A look at a recent House Financial Services Committee meeting.
In Senate Intelligence Hearing, Should U.S. Outbound Investment to China be Monitored?
Some in the Senate, like Sen. Bob Casey, say Washington needs to monitor what type of investment corporate America is making in China.
UN Finally Weighs in on China’s Breach of International Human Rights Laws
The UN Uyghur report called the situation in Xinjiang an international human rights crime. Who will be first to sue? And why are Vanguard and BlackRock allowed to invest in banned companies?
What We Need and Definitely Don’t Need from the Indo-Pacific Economic Framework
CPA economist Jeff Ferry talks about IPEF. What should Washington focus on, and what they should outright avoid.
South Korea’s Concerns Over Inflation Act EV Tax Credit Shows Need for Managed Trade
South Korea does not like the Inflation Reduction Act’s special treatment of North American-made EVs. What can Washington do about it?
Meet New CPA Board Member Julianna Keeling
Saving the planet, one to-go Container at a time, new CPA board member Julianna Keeling started her business like many entrepreneurs do – in her garage.
Trade Deficit Declines by 12% in July as Economic Slowdown Begins
The July trade deficit fell to its lower level of the year, a sign of a slowing economy. However, if trends continue, the goods deficit will break another record in 2022.
CPA Chief Takes Slings & Arrows on Trade Policy, Inflation
At the Washington International Trade Association, agreement that removing tariffs will have almost no impact on inflation. Disagreement over whether we should have them anyway.
China’s Five-Year Plan for Biotech Making it Increasingly Attractive for Global Pharma
The China pharmaceutical industry is taking a multi-pronged approach to becoming a dominant player in Asia. Maybe even the world.